KPTI Logo

Karyopharm Therapeutics Inc (KPTI) Stock Forecast & Price Prediction

Live KPTI Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$0.62

-0.01 (-1.27%)

12 Month Price Forecast For KPTI

$0.62
Current Price
$79.03M
Market Cap
7 Ratings
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to KPTI Price Forecasts

+1,023.6%
To High Target of $7.00
+702.6%
To Median Target of $5.00
+221.0%
To Low Target of $2.00

KPTI Price Momentum

0.0%
1 Week Change
-13.9%
1 Month Change
-53.7%
1 Year Change
-8.8%
Year-to-Date Change
-63.4%
From 52W High of $1.70
+7.2%
From 52W Low of $0.58

๐Ÿค” Considering Karyopharm (KPTI)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 3:54 AM UTC

KPTI Analyst Ratings & Price Targets

Based on our analysis of 13 Wall Street analysts, KPTI has a bullish consensus with a median price target of $5.00 (ranging from $2.00 to $7.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $0.62, the median forecast implies a 702.6% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Edward White at HC Wainwright & Co., projecting a 1,023.6% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

KPTI Analyst Consensus

6
Buy
1
Hold
0
Sell

KPTI Price Target Range

Low
$2.00
Average
$5.00
High
$7.00
Current: $0.62

Latest KPTI Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for KPTI.

Date Firm Analyst Rating Change Price Target
Feb 10, 2025 RBC Capital Brian Abrahams Outperform Reiterates $3.00
Jan 15, 2025 HC Wainwright & Co. Edward White Buy Reiterates $7.00
Nov 6, 2024 HC Wainwright & Co. Edward White Buy Reiterates $7.00
Nov 6, 2024 Piper Sandler Christopher Raymond Overweight Maintains $5.00
Nov 1, 2024 HC Wainwright & Co. Edward White Buy Reiterates $7.00
Aug 7, 2024 HC Wainwright & Co. Edward White Buy Reiterates $7.00
Aug 7, 2024 Baird Mitch Collett Outperform Maintains $5.00
Aug 7, 2024 RBC Capital Brian Abrahams Outperform Reiterates $3.00
Jun 28, 2024 HC Wainwright & Co. Edward White Buy Maintains $7.00
Jun 3, 2024 HC Wainwright & Co. Edward White Buy Reiterates $8.00
May 9, 2024 HC Wainwright & Co. Edward White Buy Reiterates $8.00
Mar 1, 2024 HC Wainwright & Co. Edward White Buy Maintains $8.00
Nov 3, 2023 RBC Capital Brian Abrahams Outperform Maintains $3.00
Nov 3, 2023 Piper Sandler Christopher Raymond Overweight Maintains $5.00
Aug 7, 2023 Morgan Stanley Michael Ulz Equal-Weight Maintains $4.00
Aug 3, 2023 RBC Capital Brian Abrahams Outperform Maintains $4.00
Aug 3, 2023 HC Wainwright & Co. Edward White Buy Reiterates $10.00
Aug 3, 2023 Piper Sandler Christopher Raymond Overweight Maintains $7.00
Jul 26, 2023 Wedbush David Nierengarten Neutral Maintains $4.00
Jul 26, 2023 HC Wainwright & Co. Edward White Buy Reiterates $10.00

Stocks Similar to Karyopharm Therapeutics Inc

The following stocks are similar to Karyopharm based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Karyopharm Therapeutics Inc (KPTI) Financial Data

Karyopharm Therapeutics Inc has a market capitalization of $79.03M with a P/E ratio of -0.5x. The company generates $148.44M in trailing twelve-month revenue with a -58.9% profit margin.

Revenue growth is +7.7% quarter-over-quarter, while maintaining an operating margin of -67.8% and return on equity of +105.1%.

Valuation Metrics

Market Cap $79.03M
Enterprise Value $213.31M
P/E Ratio -0.5x
PEG Ratio -0.9x
Price/Sales 0.5x

Growth & Margins

Revenue Growth (YoY) +7.7%
Gross Margin +96.6%
Operating Margin -67.8%
Net Margin -58.9%
EPS Growth +7.7%

Financial Health

Cash/Price Ratio +171.1%
Current Ratio 3.0x
Debt/Equity -1.7x
ROE +105.1%
ROA -34.3%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Karyopharm Therapeutics Inc logo

Karyopharm Therapeutics Inc (KPTI) Company Overview

About Karyopharm Therapeutics Inc

What They Do

Develops drugs for cancer treatment.

Business Model

Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs targeting nuclear export mechanisms. The company generates revenue primarily through the commercialization of its lead compound, XPOVIO, and other developing drug candidates through various licensing and distribution agreements with partners for oncology indications.

Additional Information

The company's pipeline includes several promising compounds like Selinexor and ELTANEXOR, targeting various hematological and solid tumors. Karyopharm has strategic collaborations with notable pharmaceutical companies, enhancing its development capabilities and market reach. Established in 2008 and based in Newton, Massachusetts, Karyopharm is positioned to capitalize on the growing demand for innovative cancer therapies.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

325

CEO

Mr. Richard A. Paulson M.B.A.

Country

United States

IPO Year

2013

Karyopharm Therapeutics Inc (KPTI) Latest News & Analysis

KPTI stock latest news image
Quick Summary

Karyopharm Therapeutics granted 28,000 restricted stock units to three new hires, signaling growth and investment in talent as a commercial-stage cancer therapy company.

Why It Matters

The granting of RSUs to new hires indicates Karyopharm's commitment to talent acquisition, potentially driving innovation and growth, which can enhance shareholder value.

Source: PRNewsWire
Market Sentiment: Neutral
KPTI stock latest news image
Quick Summary

Karyopharm Therapeutics anticipates top-line data from the Phase 3 SENTRY trial for Selinexor in myelofibrosis in 2H 2025. Preliminary 2024 revenues estimated at $145M, with $113M from XPOVIO.

Why It Matters

The upcoming Phase 3 SENTRY trial data could reshape myelofibrosis treatment, impacting Karyopharm's market position. Leadership changes and projected revenues indicate strategic shifts and growth potential.

Source: PRNewsWire
Market Sentiment: Neutral
KPTI stock latest news image
Quick Summary

Karyopharm Therapeutics Inc. has appointed Lori Macomber as Executive Vice President, Chief Financial Officer, and Treasurer, effective January 3, 2025.

Why It Matters

Leadership changes can impact a company's strategic direction and financial stability, influencing investor confidence and stock performance in Karyopharm Therapeutics.

Source: PRNewsWire
Market Sentiment: Neutral
KPTI stock latest news image
Quick Summary

Karyopharm Therapeutics has appointed Brendan Strong as Senior VP of Investor Relations and Corporate Communications, enhancing its leadership in investor engagement.

Why It Matters

Brendan Strong's appointment may enhance Karyopharm's communication strategy, potentially improving investor confidence and attracting interest in its cancer therapies.

Source: PRNewsWire
Market Sentiment: Neutral
KPTI stock latest news image
Quick Summary

Karyopharm Therapeutics is meeting with the FDA to discuss the treatment landscape for endometrial cancer and its Phase 3 XPORT-EC-042 trial implications.

Why It Matters

Karyopharm's FDA discussions could impact its Phase 3 trial outcomes and regulatory approval, influencing stock performance and investor sentiment in the biotech sector.

Source: PRNewsWire
Market Sentiment: Neutral
KPTI stock latest news image
Quick Summary

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3 at 11:30 a.m.

Why It Matters

Karyopharm's participation in the Piper Sandler Healthcare Conference may signal potential insights into future developments, impacting investor sentiment and stock performance.

Source: PRNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About KPTI Stock

What is Karyopharm Therapeutics Inc's (KPTI) stock forecast for 2025?

Based on our analysis of 13 Wall Street analysts, Karyopharm Therapeutics Inc (KPTI) has a median price target of $5.00. The highest price target is $7.00 and the lowest is $2.00.

Is KPTI stock a good investment in 2025?

According to current analyst ratings, KPTI has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.62. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for KPTI stock?

Wall Street analysts predict KPTI stock could reach $5.00 in the next 12 months. This represents a 702.6% increase from the current price of $0.62. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Karyopharm Therapeutics Inc's business model?

Karyopharm Therapeutics Inc. operates as a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing novel drugs targeting nuclear export mechanisms. The company generates revenue primarily through the commercialization of its lead compound, XPOVIO, and other developing drug candidates through various licensing and distribution agreements with partners for oncology indications.

What is the highest forecasted price for KPTI Karyopharm Therapeutics Inc?

The highest price target for KPTI is $7.00 from Edward White at HC Wainwright & Co., which represents a 1,023.6% increase from the current price of $0.62.

What is the lowest forecasted price for KPTI Karyopharm Therapeutics Inc?

The lowest price target for KPTI is $2.00 from at , which represents a 221.0% increase from the current price of $0.62.

What is the overall KPTI consensus from analysts for Karyopharm Therapeutics Inc?

The overall analyst consensus for KPTI is bullish. Out of 13 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $5.00.

How accurate are KPTI stock price projections?

Stock price projections, including those for Karyopharm Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.